A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The world journal of biological psychiatry Jg. 12; H. 7; S. 501 - 515
Hauptverfasser:	Serretti, Alessandro, Olgiati, Paolo, Bajo, Emanuele, Bigelli, Marco, De Ronchi, Diana
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Informa Healthcare 01.10.2011 Taylor & Francis
Schlagworte:	antidepressants Antidepressive Agents - economics Antidepressive Agents - therapeutic use Bupropion - economics Bupropion - therapeutic use Citalopram - economics Citalopram - therapeutic use Computer Simulation cost-benefit Cost-Benefit Analysis - methods Depression Depressive Disorder, Major - drug therapy Depressive Disorder, Major - economics Depressive Disorder, Major - genetics Genetic Testing - economics Humans Meta-Analysis as Topic Models, Psychological pharmacoeconomics pharmacogenetics Pharmacogenetics - economics Pharmacogenetics - methods Serotonin Plasma Membrane Transport Proteins
ISSN:	1562-2975, 1814-1412, 1814-1412
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!